Revisiting the Genetics of Hypophosphatasia
Journal of Inherited Metabolic Disease · 2025-11 · 48 (6)
DOI: 10.1002/jimd.70083 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 05.10.2025. Verfasst von Priya S Kishnani und 8 weiteren Autor:innen. Beteiligte Einrichtung: Duke University Medical Center, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Hypophosphatasia, Alkaline Phosphatase. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alexion, AstraZeneca Rare Disease, Alexion Pharmaceuticals.
Abstract (Originalsprache)
Hypophosphatasia (HPP) is a rare, inherited monogenic disorder that is typically caused by variants in the tissue‐nonspecific alkaline phosphatase ( ALPL ) gene. Genetic testing for ALPL variant(s) to confirm the diagnosis in patients with suspected HPP is a standard practice based on availability. This review attempts to improve the current understanding of the genetics of HPP as it addresses five key related topics: (1) HPP patterns of inheritance and the relationship between HPP genotype and phenotype, (2) how the disease can manifest (including specific genotypes) in heterozygotes, (3) potential reasons why some patients have persistently low alkaline phosphatase activity yet lack an ALPL variant, (4) the implications of and resources for variants of uncertain significance (VUS), and (5) recent information on genetic testing in fetuses and newborns. We summarize pertinent information applicable in daily clinical practice, with the objective of preventing missed, delayed, or incorrect HPP diagnoses and improving patient care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Duke University Medical Center, Durham, North Carolina, USA.
- ISEIKAI International General Hospital, Osaka, Japan.
- Global Medical Affairs, Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, USA.
- Centre for Genomics Research, Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Boston, Massachusetts, USA.
- Bioinformatics and Data Science, Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, USA.
- Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK.
ORCID-Profile: Priya S Kishnani
Förderung
- Alexion, AstraZeneca Rare Disease
- Alexion Pharmaceuticals
Zitieren
APA
Kishnani, P. S., Rehder, C., Ozono, K., Pérez-López, J., Del Angel, G., Mowrey, W. R., Balasubramanian, M., Högler, W., & Rush, E. T. (2025). Revisiting the Genetics of Hypophosphatasia. Journal of Inherited Metabolic Disease, 48(6). https://doi.org/10.1002/jimd.70083
Vancouver
Kishnani PS, Rehder C, Ozono K, Pérez-López J, Del Angel G, Mowrey WR, et al. Revisiting the Genetics of Hypophosphatasia. Journal of Inherited Metabolic Disease. 2025;48(6). doi:10.1002/jimd.70083
BibTeX
@article{Kishnani2025,
author = {Kishnani, Priya S and Rehder, Catherine and Ozono, Keiichi and Pérez-López, Jordi and Del Angel, Guillermo and Mowrey, William R and Balasubramanian, Meena and Högler, Wolfgang and Rush, Eric T},
title = {Revisiting the Genetics of Hypophosphatasia},
journal = {Journal of Inherited Metabolic Disease},
year = {2025},
volume = {48},
number = {6},
doi = {10.1002/jimd.70083}
}
EUVIMED